Full version: Panel "How can the UK add five years of healthy lifespan by 2030" скачать в хорошем качестве

Full version: Panel "How can the UK add five years of healthy lifespan by 2030"

https://thelongevityforum.com/ This panel will explore the recent advances in pro-longevity therapies, including small molecules, stem cells, regenerative medicine , microbiome and gene therapy. All of these are, to varying degrees, in human trials and the combination of these exciting developments and the fact that ageing pathways have been proven to be malleable, make the bioengineering of human beings to live longer and more robustly a strong likelihood, rather than an historically improbable aspiration. Indeed, it is clear that the science of biogerontology is rapidly catching up with the desire of most of us to live longer and in better health. Charles Alessi Charles Alessi is the Chief Clinical Officer for HIMSS International. HIMSS is a global voice, advisor and thought leader of health transformation through health information and technology with a unique breadth and depth of expertise and capabilities to improve the quality, safety, and efficiency of health, healthcare and care outcomes. Before joining HIMSS in 2018, Alessi has acted in numerous external positions for governments and executive agencies on a national and international level. Alessi brings more than 25 years of experience in global healthcare policy and clinical practice to HIMSS. Most recently, he chaired the National Association of Primary Care (NAPC), has served as an adjunct research professor for Clinical Neurosciences at the Schulich School of Medicine for the University of Western Ontario, Canada, and as executive director of the Global International Care Delivery Alliance. Alessi is also the senior advisor for Public Health England, leading national policy implementation, productive healthy ageing and is currently contributing to the global World Health Organization guidelines for dementia risk reduction. Alessi has also contributed his expertise to multiple international publications such as the British Journal of General Practice, addressing topics such as health and social care contract and health policy. He has lectured and led keynote addresses for healthcare engagements taking place on every continent (except Antarctica). Greg Bailey (moderator) Dr Bailey is the CEO of Juvenescence Limited a company that develops therapeutics, so people can live longer, healthy. Juvenescence develops drugs, IP protected consumer products and other therapeutic modalities to slow ageing and increase a healthy lifespan. The company uses AI to augment its drug discovery and drug development programs in partnership with Insilico Medicine and NetraMark. Lynne Cox Professor Cox is a biogerontologist at the University of Oxford. She runs a research group focused on understanding the basic molecular mechanisms underlying ageing, with the aim of using that understanding to improve health in later life, by developing treatments to alleviate the diseases of old age. She is a Trustee of the British Society for Research on Ageing, Fellow of the Royal Society of Biology, and co-founder of the Oxford Ageing Network, OxAgeN, which now forms part of the wider Oxford collaboration on ageing. In 2015, she received the US Glenn Foundation award, presented at the House of Lords, for research into the biological mechanisms of ageing. She serves on the All-Party Parliamentary Group on Longevity, the Clinical and Translational theme panel of the Biochemical Society, is a primary international member of the Norwegian NO-Age consortium, and has just been elected co-chair of a new EU special interest group of the European Geriatric Medicine Society on the biology of ageing. Tina Woods Tina Woods is CEO and Founder of Collider Health, a health innovation catalyst working with organisations in both private and public sectors (corporates, investors, third sector, government, SMEs and start-ups) to accelerate innovation. Tina is an ecosystem architect and builds collaborative networks and strategic partnerships to transform health with sustainable impact at scale. Tina and her team at Collider Health work with NHS X and the National AHSN Network to build the AI ecosystem for the NHS, with AXA health insurer on their corporate innovation programme Health Tech & You. She has been involved in consortia development for the Healthy Ageing Industrial Strategy Challenge Fund with UK Research & Innovation. Tina is also CEO and Co-founder of Longevity International, which runs the All-Party Parliamentary Group for Longevity, developing a UK National Strategy to help deliver 5 extra years of healthy life expectancy to all UK citizens by 2035 while closing the social gap to ensure democratic access to the ‘longevity dividend’. Tina is also CEO & Founder of Collider Science, that aims to inspire young people in science and technology and equip them with the skills for the future. Tina writes regularly for Forbes, D/sruption and other media channels, and is currently writing a book, ‘Live Longer with AI’.